DGI-019 Cisplatin Desensitisation Protocol
Background Hypersensitivity reactions are adverse events that represent a challenge, because in some cases there isn’t an alternative treatment. Consequently, the only option is to desensitise the patient. Purpose To describe a cisplatin desensitisation protocol (CDP) in a patient with a previous an...
Saved in:
Published in | European journal of hospital pharmacy. Science and practice Vol. 20; no. Suppl 1; p. A102 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
London
BMJ Publishing Group LTD
01.03.2013
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Background Hypersensitivity reactions are adverse events that represent a challenge, because in some cases there isn’t an alternative treatment. Consequently, the only option is to desensitise the patient. Purpose To describe a cisplatin desensitisation protocol (CDP) in a patient with a previous anaphylactic reaction. Materials and Methods Male diagnosed with lung cancer, who started chemotherapy with cisplatin 75 mg/m² and oral vinorelbine 60 mg/m². During the cisplatin infusion, he suffered an anaphylactic reaction, so it was decided to perform skin tests, to confirm the possible association with the cytostatic. Due to the cross-reactivity between platinum salts, these tests were performed with all similar substances. Stock solutions used: cisplatin 1 mg/ml, carboplatin 5 mg/ml and oxaliplatin 10 mg/ml. Dilutions prepared for intradermal administration: 1/10000, 1/1000, 1/100 and 1/10. Results Cisplatin skin tests were positive for the stock solution and negative for the other dilutions. All the other platinum salts were negative, so we developed a protocol for administering the next cycle of cisplatin. The CDP consisted of 12 stages in which to administer the total dose (140 mg).Three solutions (250 ml) were prepared with dilutions 1/100, 1/10 and 1/1. The 1/100 solution (0.0056 mg/ml) was administered at 9.25 ml in 1 hour in 4 stages (administration rate increments every 15 minutes: 2 ml/h, 5 ml/h, 10 ml/h and 20 ml/h). The 1/10 solution (0.056 mg/ml) was administered at 18.75 ml in 1 hour in 4 steps (starting with 5 ml/h and doubling the rate every 15 minutes until 40 ml/h). Solution 1/1 (0.56 mg/ml) was administered completely, starting with 10 ml/h and increasing every 15 min to 20, 40 and 80 ml/h, being the final perfusion rate. It was performed under medical supervision, taking in total 5 hours and 37 minutes. The patient didn’t have any complications. Conclusions In this patient, the CDP developed enabled the chemotherapy to be given safely. All this was possible by the interdisciplinary collaboration of allergy, oncology and pharmacy services. No conflict of interest. |
---|---|
AbstractList | Background Hypersensitivity reactions are adverse events that represent a challenge, because in some cases there isn’t an alternative treatment. Consequently, the only option is to desensitise the patient.PurposeTo describe a cisplatin desensitisation protocol (CDP) in a patient with a previous anaphylactic reaction.Materials and MethodsMale diagnosed with lung cancer, who started chemotherapy with cisplatin 75 mg/m² and oral vinorelbine 60 mg/m². During the cisplatin infusion, he suffered an anaphylactic reaction, so it was decided to perform skin tests, to confirm the possible association with the cytostatic.Due to the cross-reactivity between platinum salts, these tests were performed with all similar substances. Stock solutions used: cisplatin 1 mg/ml, carboplatin 5 mg/ml and oxaliplatin 10 mg/ml. Dilutions prepared for intradermal administration: 1/10000, 1/1000, 1/100 and 1/10.ResultsCisplatin skin tests were positive for the stock solution and negative for the other dilutions. All the other platinum salts were negative, so we developed a protocol for administering the next cycle of cisplatin.The CDP consisted of 12 stages in which to administer the total dose (140 mg).Three solutions (250 ml) were prepared with dilutions 1/100, 1/10 and 1/1. The 1/100 solution (0.0056 mg/ml) was administered at 9.25 ml in 1 hour in 4 stages (administration rate increments every 15 minutes: 2 ml/h, 5 ml/h, 10 ml/h and 20 ml/h). The 1/10 solution (0.056 mg/ml) was administered at 18.75 ml in 1 hour in 4 steps (starting with 5 ml/h and doubling the rate every 15 minutes until 40 ml/h). Solution 1/1 (0.56 mg/ml) was administered completely, starting with 10 ml/h and increasing every 15 min to 20, 40 and 80 ml/h, being the final perfusion rate. It was performed under medical supervision, taking in total 5 hours and 37 minutes. The patient didn’t have any complications.Conclusions In this patient, the CDP developed enabled the chemotherapy to be given safely. All this was possible by the interdisciplinary collaboration of allergy, oncology and pharmacy services.No conflict of interest. Background Hypersensitivity reactions are adverse events that represent a challenge, because in some cases there isn't an alternative treatment. Consequently, the only option is to desensitise the patient. Purpose To describe a cisplatin desensitisation protocol (CDP) in a patient with a previous anaphylactic reaction. Materials and Methods Male diagnosed with lung cancer, who started chemotherapy with cisplatin 75 mg/m² and oral vinorelbine 60 mg/m². During the cisplatin infusion, he suffered an anaphylactic reaction, so it was decided to perform skin tests, to confirm the possible association with the cytostatic. Due to the cross-reactivity between platinum salts, these tests were performed with all similar substances. Stock solutions used: cisplatin 1 mg/ml, carboplatin 5 mg/ml and oxaliplatin 10 mg/ml. Dilutions prepared for intradermal administration: 1/10000, 1/1000, 1/100 and 1/10. Results Cisplatin skin tests were positive for the stock solution and negative for the other dilutions. All the other platinum salts were negative, so we developed a protocol for administering the next cycle of cisplatin. The CDP consisted of 12 stages in which to administer the total dose (140 mg).Three solutions (250 ml) were prepared with dilutions 1/100, 1/10 and 1/1. The 1/100 solution (0.0056 mg/ml) was administered at 9.25 ml in 1 hour in 4 stages (administration rate increments every 15 minutes: 2 ml/h, 5 ml/h, 10 ml/h and 20 ml/h). The 1/10 solution (0.056 mg/ml) was administered at 18.75 ml in 1 hour in 4 steps (starting with 5 ml/h and doubling the rate every 15 minutes until 40 ml/h). Solution 1/1 (0.56 mg/ml) was administered completely, starting with 10 ml/h and increasing every 15 min to 20, 40 and 80 ml/h, being the final perfusion rate. It was performed under medical supervision, taking in total 5 hours and 37 minutes. The patient didn't have any complications. Conclusions In this patient, the CDP developed enabled the chemotherapy to be given safely. All this was possible by the interdisciplinary collaboration of allergy, oncology and pharmacy services. No conflict of interest. |
Author | Olivares-Pallerols, R Pérez-Serrano-Lainosa, MD Navarro-Ferrando, JP Sangrador-Pelluz, C Martinez-García, M Soler-Company, E |
Author_xml | – sequence: 1 givenname: C surname: Sangrador-Pelluz fullname: Sangrador-Pelluz, C organization: Hospital Arnau de Vilanova, Pharmacy, Valencia, Spain – sequence: 2 givenname: M surname: Martinez-García fullname: Martinez-García, M organization: Hospital Arnau de Vilanova, Allergy, Valencia, Spain – sequence: 3 givenname: MD surname: Pérez-Serrano-Lainosa fullname: Pérez-Serrano-Lainosa, MD organization: Hospital Arnau de Vilanova, Pharmacy, Valencia, Spain – sequence: 4 givenname: R surname: Olivares-Pallerols fullname: Olivares-Pallerols, R organization: Hospital Arnau de Vilanova, Pharmacy, Valencia, Spain – sequence: 5 givenname: JP surname: Navarro-Ferrando fullname: Navarro-Ferrando, JP organization: Hospital Arnau de Vilanova, Pharmacy, Valencia, Spain – sequence: 6 givenname: E surname: Soler-Company fullname: Soler-Company, E organization: Hospital Arnau de Vilanova, Pharmacy, Valencia, Spain |
BookMark | eNqNkM1KAzEURoNUsNa-Q8GtqTf_yVJarYWCLnQdkk6GTmknYzJduHPji_oknTLqUlzde-F894NziQZ1rANCEwJTQpi8DdtNs3FpjykQhgGAKjmlWpyhIQWusDGSD353IS_QOOfKg2BMG87MEN3MF0sMxHx9fM6q3OxcW9WTecihzlVb5e6M9eQ5xTau4-4KnZdul8P4e47Q68P9y-wRr54Wy9ndCnvStWBNjV4zwjnXrgTuwQhNglI6FNI4YTwPRspQgNYFMKkAShG8U14RZ4AWbISu-79Nim-HkFu7jYdUd5WWCkGVUILpvyiiNCcGjCIdpXtqnWLOKZS2SdXepXdLwJ4k2h-J9iTR9hJtJ7GLsj7q99v_p46wn3aq |
ContentType | Journal Article |
Copyright | 2013, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions Copyright: 2013 (c) 2013, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions 2013 2013, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions |
Copyright_xml | – notice: 2013, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions – notice: Copyright: 2013 (c) 2013, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions – notice: 2013 2013, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions |
DBID | AAYXX CITATION 3V. 7X7 7XB 8FI 8FJ 8FK ABUWG AFKRA BENPR BTHHO CCPQU FYUFA GHDGH K9. PQEST PQQKQ PQUKI PRINS |
DOI | 10.1136/ejhpharm-2013-000276.285 |
DatabaseName | CrossRef ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central ProQuest Central BMJ Journals ProQuest One Community College Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China |
DatabaseTitle | CrossRef ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete Health Research Premium Collection ProQuest One Academic UKI Edition BMJ Journals ProQuest One Academic ProQuest Central (Alumni) |
DatabaseTitleList | ProQuest One Academic Eastern Edition ProQuest One Academic Eastern Edition |
Database_xml | – sequence: 1 dbid: 7X7 name: Health & Medical Collection url: https://search.proquest.com/healthcomplete sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
EISSN | 2047-9964 |
EndPage | A102 |
ExternalDocumentID | 4035024331 10_1136_ejhpharm_2013_000276_285 |
GroupedDBID | 0R~ 3V. 53G 7X7 8FI 8FJ AAYAA ABKRM ABUWG ABVAJ ABWEH ADBBV ADMRH AFKRA AHMBA AHQMW AJYBZ ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BENPR BPHCQ BTHHO C45 CCPQU CXRWF EBS EJD FYUFA H13 HAJ HMCUK HYE OK1 OVD PQQKQ PROAC RHI RMJ RPM TEORI UKHRP AAYXX CITATION 7XB 8FK K9. PQEST PQUKI PRINS |
ID | FETCH-LOGICAL-b1995-8298c314448af04b09581e778ed69a59b4e966ed088d036700f5eba7b71a902d3 |
IEDL.DBID | 7X7 |
ISSN | 2047-9956 |
IngestDate | Fri Sep 13 07:29:57 EDT 2024 Fri Sep 13 04:18:01 EDT 2024 Fri Aug 23 00:57:25 EDT 2024 Wed Aug 21 03:28:44 EDT 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | Suppl 1 |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-b1995-8298c314448af04b09581e778ed69a59b4e966ed088d036700f5eba7b71a902d3 |
OpenAccessLink | https://ejhp.bmj.com/content/ejhpharm/20/Suppl_1/A102.1.full.pdf |
PQID | 1784190971 |
PQPubID | 2040966 |
ParticipantIDs | proquest_journals_2552757538 proquest_journals_1784190971 crossref_primary_10_1136_ejhpharm_2013_000276_285 bmj_primary_10_1136_ejhpharm_2013_000276_285 |
PublicationCentury | 2000 |
PublicationDate | 20130300 2013-03-00 20130301 |
PublicationDateYYYYMMDD | 2013-03-01 |
PublicationDate_xml | – month: 03 year: 2013 text: 20130300 |
PublicationDecade | 2010 |
PublicationPlace | London |
PublicationPlace_xml | – name: London |
PublicationTitle | European journal of hospital pharmacy. Science and practice |
PublicationYear | 2013 |
Publisher | BMJ Publishing Group LTD |
Publisher_xml | – name: BMJ Publishing Group LTD |
SSID | ssib053389439 ssj0000605265 ssib018287486 |
Score | 1.8912604 |
Snippet | Background Hypersensitivity reactions are adverse events that represent a challenge, because in some cases there isn’t an alternative treatment. Consequently,... Background Hypersensitivity reactions are adverse events that represent a challenge, because in some cases there isn't an alternative treatment. Consequently,... |
SourceID | proquest crossref bmj |
SourceType | Aggregation Database Publisher |
StartPage | A102 |
SubjectTerms | Chemotherapy Lung cancer |
Title | DGI-019 Cisplatin Desensitisation Protocol |
URI | http://dx.doi.org/10.1136/ejhpharm-2013-000276.285 https://www.proquest.com/docview/1784190971/abstract/ https://www.proquest.com/docview/2552757538/abstract/ |
Volume | 20 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1NS8MwGA77uHgRRcXpHD14XF2TtmlyEt2HU3AMcbBbaJoEHdjVbd69-Ef9JeZt142BCJ5DD3369v3K8z4vQpcBVyaQPnElgdYNNdiF8UyXqMQ3NmBgE8I08uOIDifBwzScVtCwnIUBWmXpE3NHreYJ9Mg7BKTCbG7hs04soQuQrDrX2bsL-6PgnnW9TKOK6pjYtMJadjTdBFacy7pvhdJsjgO643zTjfEo6J4A35GAdAGMe5a0H5929OwlAyFpa1KwCwFKOXpFYP1yVb7NdiParkPPo9TgAO2v00vnprCHQ1TR6RFq9-7ubTHPvz-_uq_LDNhvqdODsSMgbBV0Hme8mK_m1iqO0WTQf-4O3fWWBFfm49WMcJb4ti4KWGy8QNqciWEdRUwryuOQy0DbkkYr606UB3Jtngm1jCMZ4Zh7RPknqJbOU32KnIBqzCQLPWXRiWLKg8QYTpkhhio_Vg3Utu8rskIHQ-T1g09FCY8AeEQBj7DwNBAugfnHM80SQbH-m5YCw-UoB7WrX4-3pnH29_E52iu-IFDImqi2WnzoC5tTrGQrN5cWqt_2R-OnHySjw58 |
link.rule.ids | 315,786,790,12083,21416,27957,27958,31754,33779,43345,43840,74102,74659 |
linkProvider | ProQuest |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3JTsMwELWgPcAFgQCxFMiBYwPxEsc-IehCy1IhRKXerDi2BUi0hZY7F36UL8GTBYSEkDhbOeRlMpvfvEHokEnjmKYk1ARaN9zhEMYzQ2Iy6nzAwC6GaeTrAe8N2cUoHpUNt1lJq6x8Yu6ozSSDHvkxAakwn1tQcTJ9DmFrFNyulis0FlGdUV-q1FD9rDO4ua0sCudy7t8CaT63Ab1x-dWFiTjonQDPkYBkAYx5VnQfyo_t4_0UBKS9KcEOBCjh-BGBtcuL-unxZyT76cjz6NRdRStlWhmcFnawhhbseB012-d9X8TLj7f31sNsCqy3cdCGcSMgahU0nuDmZTKfeGvYQMNu567VC8vtCKHOx6oFkSKjvh5iInUR0z5XEtgmibCGyzSWmllfyljj3YiJQKYtcrHVaaITnMqIGLqJauPJ2G6hgHGLhRZxZDw6Scoly5yTXDjiuKGp2UZN_75qWuhfqLxuoFxV8CiARxXwKA_PNsIVMP94plEhqMq_aKYwXIpKULn69fjbJHb-Pj5AS7276yt11R9c7qLl4msCjayBavOXV7vn84q53i-N5xO-3cKe |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV27TsMwFLWgSIgFgQBRKNCBsaGJ4zj2hFBLaXlUHajUzYpjW1CJJLRlZ-FH-RJ882hVCSExWxlycnNfPvdchC4JV4ZIHzsSQ-uGGs-B8UwHq9g3NmB4JoBp5Kch7Y_J_SSYlPyneUmrrHxi7qhVGkOPvI1BKszmFj5rm5IWMer2rrN3BzZIwU1ruU5jE23ZKOnCNoNwsgytXi7svpJKs1kOKI_zZT_GpaB8AoxHDOIFMPBZEX982tbTlwykpK1RwTYEKOboFYYFzJvybboe09Zdeh6nentot0wwmzeFReyjDZ0coFb3bmDLef79-dV5nWfAf0uaXRg8AspWQehpjmbpIrV2cYjGvdvnTt8p9yQ4Mh-wZpiz2LeVEWGRcYm0WRPzdBgyrSiPAi6JtkWNVtahKBcE21wTaBmFMvQi7mLlH6Fakib6GDUJ1R6TLHCVRSeMKCexMZwygw1VfqTqqGXfV2SFEobIKwifigoeAfCIAh5h4akjrwLmH880KgRF-T_NhQfXoxz0rn49XhnHyd_HF2jbWo14HAwfTtFO8TGBT9ZAtcXsQ5_ZBGMhz3PL-QGr2sVk |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=DGI-019%E2%80%85Cisplatin+Desensitisation+Protocol&rft.jtitle=European+journal+of+hospital+pharmacy.+Science+and+practice&rft.au=Sangrador-Pelluz%2C+C&rft.au=Martinez-Garc%C3%ADa%2C+M&rft.au=P%C3%A9rez-Serrano-Lainosa%2C+MD&rft.au=Olivares-Pallerols%2C+R&rft.date=2013-03-01&rft.issn=2047-9956&rft.eissn=2047-9964&rft.volume=20&rft.issue=Suppl+1&rft.spage=A102&rft_id=info:doi/10.1136%2Fejhpharm-2013-000276.285&rft.externalDBID=ttp%3A%2F%2Fejhp.bmj.com%2Fcontent%2F20%2FSuppl_1%2FA102.1.full.pdf |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2047-9956&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2047-9956&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2047-9956&client=summon |